Praluzatamab Biosimilar – Anti-ALCAM, CD166 mAb – Research Grade

Description of Praluzatamab Biosimilar - Anti-ALCAM, CD166 mAb - Research Grade

Introduction

Praluzatamab Biosimilar, also known as Anti-ALCAM or CD166 monoclonal antibody, is a promising therapeutic antibody that targets ALCAM (Activated Leukocyte Cell Adhesion Molecule). This antibody has shown great potential in cancer treatment and has been extensively studied in preclinical and clinical trials. In this article, we will provide a scientific description of the structure, activity, and application of Praluzatamab Biosimilar.

Structure of Praluzatamab Biosimilar

Praluzatamab Biosimilar is a monoclonal antibody that specifically binds to ALCAM, a cell adhesion molecule that plays a crucial role in cell-cell interactions. The antibody is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to ALCAM, while the constant region is involved in effector functions such as complement activation and antibody-dependent cellular cytotoxicity (ADCC).

Mechanism of Action

Once bound to ALCAM, Praluzatamab Biosimilar blocks the interaction between ALCAM and its ligand, resulting in decreased cell adhesion and migration. This mechanism is particularly important in cancer treatment, as ALCAM is overexpressed in various types of cancer and is associated with tumor progression and metastasis. By targeting ALCAM, Praluzatamab Biosimilar inhibits tumor growth and metastasis, making it a promising therapeutic option for cancer patients.

Activity of Praluzatamab Biosimilar

Studies have shown that Praluzatamab Biosimilar has potent anti-tumor activity in both in vitro and in vivo models. In a preclinical study, Praluzatamab Biosimilar demonstrated significant inhibition of tumor growth in a xenograft model of colon cancer. This effect was attributed to the antibody’s ability to block ALCAM-mediated cell adhesion and migration. Furthermore, Praluzatamab Biosimilar has also been shown to induce tumor cell death through ADCC, making it a promising therapeutic option for cancers that are resistant to traditional chemotherapy.

Clinical Applications

Praluzatamab Biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including breast, lung, and colorectal cancers. In a phase I clinical trial, Praluzatamab Biosimilar showed promising results in patients with advanced solid tumors, with a manageable safety profile and encouraging anti-tumor activity. The antibody is also being studied in combination with other cancer therapies, such as chemotherapy and immune checkpoint inhibitors, to determine its potential in improving treatment outcomes.

Research Grade Praluzatamab Biosimilar

In addition to its therapeutic potential, Praluzatamab Biosimilar is also available as a research grade antibody for use in various research applications. This antibody can be used in various techniques such as flow cytometry, immunohistochemistry, and Western blotting to study the expression and function of ALCAM in different cell types and tissues. The research grade Praluzatamab Biosimilar is produced under strict quality control measures to ensure its purity, specificity, and activity.

Conclusion

In summary, Praluzatamab Biosimilar is a promising therapeutic antibody that specifically targets ALCAM, a cell adhesion molecule that plays a crucial role in cancer progression and metastasis. Its unique mechanism of action and potent anti-tumor activity make it a promising candidate for the treatment of various types of cancer. Furthermore, its availability as a research grade antibody allows for further investigation of ALCAM and its role in cancer and other diseases. With ongoing clinical trials, Praluzatamab Biosimilar has the potential to become a valuable addition to the arsenal of cancer treatments.